JEVTANA Black Triangle Refused For Men With Advanced Prostate Cancer - science20.com

The National Institute for Health and Clinical Excellence (NICE) has announced today that its decision not to approve JEVTANA[(R)Black Triangle Drug] (cabazitaxel) for use on the NHS will be upheld, following an appeal from Sanofi. This decision could ...

Anger as NHS deem prostate cancer drug Cabazitaxel 'too expensive' - The Independent

Cabazitaxel, which is marketed as Jevtana, can extends the life of late-stage patients by an average of three months. The National Institute for Health and Clinical Excellence (Nice), which decides which drugs should be offered on the NHS, today confirmed ...

UK cost body backs Botox for some migraine patients - Reuters

SANOFI'S JEVTANA REBUFFED In a separate statement, NICE confirmed its decision not to recommend use of Sanofi's prostate cancer drug Jevtana on Britain's state health service, given its limited ability to extend life, its side effects and its cost.

Sanofi: Kiss This Stock Goodbye - Seekingalpha.com

Sanofi experienced yet another blow when the National Institute for Health and Clinical Excellence (NICE) rejected its cancer drug Jevtana. The idea was that the drug would be used as a second line treatment for prostate cancer in combination with ...

Disappointment for Men With Advanced Prostate Cancer As Life-Extending Drug[1]Refused by NICE - Yahoo Finance

Warning of an emerging 'postcode lottery' for men with advanced prostate cancer as NICE upholds its decision not to approve JEVTANA [®▼] (cabazitaxel) for use on the NHS Professor Jonathan Waxman, Imperial College London, comments "This ...

Botox given go-ahead for migraine sufferers - The Guardian

Sir Andrew Dillon, Nice's chief executive, said at £22,000 per patient, the drug cabazitaxel, which is marketed as Jevtana, did not represent value for money for the NHS. There are also concerns about its side-effects, he added. But prostate ...

Second Al Megrahi prostate cancer drug 'too expensive' for NHS - Daily Telegraph

Nice calculated that cabazitaxel, marketed by drugs firm Sanofi as Jevtana, would cost £22,000 per patient. It was also associated with "a number of side effects", said Sir Andrew. Nice's decision on cabazitaxel is final, so the decision cannot be altered.

Dendreon Management Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript) - Seekingalpha.com

But currently the drug in the space along with Docetaxel Taxotere chemotherapeutic regimen, and you’ve seen Jevtana has been approved as Zytiga for the chemo refractory. I think that you will see Zytiga data coming out and we do expect to see that ...